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JNK1ss in cardiovascular diseases. The extracellular matrix (ECM) of the vasculature is
a major target of inﬂammatory cytokines, and TNFα regulates ECM metabolism by affecting collagen
production. In this study, we have examined the pathways mediating TNFα-induced suppression of prolyl-4
hydroxylase alpha1 (P4Hα1), the rate-limiting isoform of P4H responsible for procollagen hydroxylation,
maturation, and organization. Using human aortic smooth muscle cells, we found that TNFα activated the
MKK4-JNK1 pathway, which induced histone (H) 4 lysine 12 acetylation within the TNFα response element
in the P4Hα1 promoter. The acetylated-H4 then recruited a transcription factor, NonO, which, in turn,
recruited HDACs and induced H3 lysine 9 deacetylation, thereby inhibiting transcription of the P4Hα1
promoter. Furthermore, we found that TNFα oxidized DJ-1, which may be essential for the NonO–P4Hα1
interaction because treatment with gene speciﬁc siRNA to knockout DJ-1 eliminated the TNFα-induced
NonO–P4Hα1 interaction and its suppression. Our ﬁndings may be relevant to aortic aneurysm and
dissection and the stability of the ﬁbrous cap of atherosclerotic plaque in which collagen metabolism is
important in arterial remodeling. Deﬁning this cytokine-mediated regulatory pathway may provide novel
molecular targets for therapeutic intervention in preventing plaque rupture and acute coronary occlusion.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Inﬂammation directly contributes to the pathogenesis of most car-
diovascular diseases, including heart failure, cardiomyopathy, athero-
sclerotic plaque rupture, and aortic aneurysm and dissection [1,2].
Inﬂammatory cytokines, such as TNFα, regulate many factors in the
pathological processes of cardiovascular diseases; however, one main
target for the actions of these cytokines is the extracellular matrix
(ECM), which is a primary structural component of the cardiovascular
system [3]. Alterations in ECMmetabolism, such as abnormal collagen
production, result in the initiation and progression of cardiovascular
diseases. Reduced collagen synthesis or excessive collagen degradation
can lead to aortic aneurysm and atherosclerotic plaque rupture [4].d at MS BCM 390, One Baylor
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l rights reserved.The ECM, which includes ﬁbrillar (collagen and elastin) and ad-
hesive proteins (laminin and ﬁbronectin), serves as the structural
framework for all 3 layers of the arterial wall. Of the more than 39
subtypes of collagens, types I and III are the most common in the
arterial wall [5]. Most of the mature collagen ﬁbers comprise 3 iden-
tical polypeptide chains called α chains, with at least 1 triple-helical
collagenous domain with repeating (Gly-X-Y)n sequences, in which
proline and 4-hydroxyproline ﬁll the X and Y positions.
Collagen synthesis and secretion require posttranslational modiﬁca-
tions of procollagens, including hydroxylation and glycosylation. Prolyl-4-
hydroxylase (P4H), an essential enzyme involved in collagenmodiﬁcation,
catalyzes the formation of hydroxyproline from proline residues located
in repeating X-Pro-Gly triplets in the procollagens. This step is required
for folding the polypeptide chains into stable triple-helical molecules
[6,7]; therefore, adequate P4H expression is essential for the formation
of functional collagen in the arterial wall and pathogenesis of vascular
diseases, e.g. atherosclerosis or aortic aneurysm [8].
P4H is composed of α and β subunits; the rate-limiting α subunit
is regulated by various cytokines [9]. Collagen synthesis is actively
regulated by cytokines, and TNFα, a cytokine released from active
1518 C. Zhang et al. / Biochimica et Biophysica Acta 1783 (2008) 1517–1528macrophages, is a major participant in the regulation of ECM me-
tabolism. We have previously shown that TNFα suppresses P4Hα1
expression. The TNFα responsive element (TaRE) is located at −32
to +18 bp of the P4Hα1 promoter; NonO (human p54nrb) binds as
a transcription factor to TaRE and mediates TNFα-mediated P4Hα1
suppression. We have further suggested that the ASK1-JNK pathway
may be the downstream pathway for the TNFα effect [10]. In the
current study, we have investigated the molecular mechanisms for
TNFα-mediated P4Hα1 suppression. In addition to NonO, we have
identiﬁed another transcription factor, DJ-1 [11,12], which was
oxidized by TNFα and required for the NonO–TaRE interaction.
Furthermore, we found that the TNFα-MKK4-JNK1 pathway may
induce acetylation at lysine 12 of histone 4, which facilitated the
NonO–TaRE interaction. Recruitment of histone deacetylases (HDACs)
resulted in deacetylation or methylation of lysine 9 at histone 3, which
inhibited P4Hα1 transcription. In this study, we have further deﬁned
the molecular events mediating the TNFα-induced suppression of
P4Hα1. Ourﬁndingsmay identify a newtherapeutic target to attenuate
inﬂammation-induced ECM disturbances and consequently cardio-
vascular diseases.
2. Materials and methods
2.1. MKK4 and JNK1 adenovirus ampliﬁcation
Wild-type and dominant negative adenovirus for MKK4 and JNK1 were used as
previously described [13,14]. HEK293 cells (ATCC, Manassas, VA) were used to amplify the
adenovirus. We infected HEK293 cells, which were cultured in 25ml ﬂasks, with adenovirus
by mixing 5 μl adenoviral vectors with 1.5 ml DMEM (Cat# 11965, Invitrogen Corp, Carlsbad,
CA) every 15min for 1 h. The infected cells were continuously cultured for 48 h before being
harvested and stored asMKK4 (1×108 PFU/ml) and JNK1 (1.5×108 PFU/ml) adenoviral stock
solutions.
2.2. Cell culture, transfection, and treatments
Human aortic smoothmuscle cells (HASMCs)were harvested from fresh human aorta
(fromorgan donors) using an explant culture technique in SMC culturemedium (Cat#311-
500 Cell Application, San Diego, CA) containing 10% fetal bovine serum (FBS) as described
earlier [15]. We cultured cells to the 4th passage before the experiments were carried out.
HASMCswere treatedwith 100 ng/ml TNFα (Cat# T6674, Sigma-Aldrich, St Louis, MO) for
8 h in 6-well plates.
To study the role of MKK4 and JNK1 in TNFα-mediated P4Hα1 suppression, wild-
type and dominant negative adenovirus MKK4 and JNK1 were used to infect HASMCs.
We mixed 50 μl HASMCs medium with 20 μl adenovirus-infected HEK293 cells, and
subjected the cell solution to 3 freeze-thaw cycles for HEK293 cell lysis and adenovirus
release. The dose-dependent effects of MKK4 or JNK1 on HASMCS were evaluated by
infecting HASMCs with MOI (multiplicity of infection) at 1, 2, 3, 6 and 10 wild-type and
dominant negative MKK4 or JNK1 adenovirus for 24 h. At the end of 24 h, MKK4- and
JNK1-treated HASMCs were harvested for mRNA measurements.
NonO, DJ-1, and hypoxia-inducible factor-1 (HIF1)-speciﬁc siRNA (100 nM) were used
for gene-speciﬁc inhibition to evaluate the roles of these proteins in TNFα-mediated
P4Hα1 suppression. In each experiment, siRNA-mediated gene silencing was allowed for
24 h before TNFα treatment. The siRNA duplex was chemically synthesized (Integrated
DNA Technologies, Houston, TX). The following siRNA sequences for the NonO gene were
used: sense, 5′rArArUrCrArUrArCrUrCrCrArArGrGrArArGrCrArUrUrU3′; antisense, 5′rAr-
ArArUrGrCrUrUrCrCrUrUrGrGrArGrUrArUrGrArUrUr3. The following siRNA sequences
were used for the DJ-1 gene: sense, 5′rArArArCrArGrGrGrArUrGrArCrCrGrUrCrUrCrCrAr-
UrU3′; antisense, 5′rArArUrGrGrArGrArCrGrGrUrCrArUrCrCrCrUrGrUrUrU'. The sequences
for siRNA of HIF1 were as follows: sense, 5′rArArCrUrArCrCrArArUrUrCrCrArArCrUrUr-
GrArArUrU3′; antisense, 5′rArArUrUrCrArArGrUrUrGrGrArArUrUrGrGrUrArGrUrU3′.
To assess the involvement of histone acetylation and deacetylation in TNFα-suppressed
P4Hα1 expression, anacardic acid (Cat#270-381-M005, Alexis Corp, Lausen, Switzerland)
was used as a histone acetylation transferase inhibitor (HATI), and trichostatin A (TSA)
(Cat#T8852-1MG Sigma) was used as an HDAC inhibitor [16–18]. P4Hα1 mRNA expression
was determined in HASMCs treated with 20 μM HATI or 500 ng/ml TSA for 24 h with or
without TNFα or JNK1 treatment.
2.3. Quantitative real-time RT-PCR
Levels of P4Hα1 mRNA were measured by quantitative real-time RT-PCR. Primers
were designed with Beacon Designer 2.0 and chemically synthesized (Integrated DNA
Technologies). The primers for P4Hα1 mRNA were sense, 5′CATGACCCTGAG ACTG-
GAAA3′; and antisense, 5′GCCAGGCACTCTTAGATACT3′. The primers for housekeeping
gene human β-actin were sense, 5′CTGGAACGGTGAAGGTGACA3′; and antisense, 5′
GGGACTTCCTGTAACAATGCA3′.
RNATrizol (Cat# 15596-018, Invitrogen)was used to extract total RNA fromHASMCs
as per manufacturer's instructions. We tested concentrations of total RNA usingspectrophotometry after extracted RNA was dissolved in a ﬁnal volume of 25 μl RNase
freewater. Reverse transcriptionwas carried out by adding 1 μg RNA in a ﬁnal volume of
20 μl. An iScript cDNA synthesis kit (Cat#170-8891, Bio-Rad, Hercules, CA) containing a
mixture of oligo(dT) and random primers was used to convert mRNA to cDNA. We used
SYBR Green I Supermix kit (cat#170-8882, Bio-Rad) for real-time PCR by adding 1 μl
cDNA from the total 20 μl reverse transcription volume. PCRwas performed in duplicate
using an iCycler iQ real-time PCR detection system for 40 cycles at 95 °C for 30 s, 55 °C for
30 s, and 72 °C for 30 s. Estimations of mRNA levels from the value of the threshold cycle
(Ct) of the real-time PCR were adjusted by that of β-actin using the formula x-fold
expression=2ΔCt (ΔCt=β-actin Ct−gene of interest Ct).
2.4. Nuclear protein extraction and immunoprecipitation
HASMCs were treated with or without TNFα for 8 h before nuclear protein
extraction. Cold PBS was used to wash cell pellets 4 times before cells were lysed on ice
and resuspended in NaCl (0.15 M). We added 65% Percoll (Cat#P4937-100ML, Sigma) to
3.5 ml tubes for gradient centrifugation at 30,000 ×g for 15 min at 4 °C. Then, the cell
lysate was added to the top of the gradient solution and centrifuged at 100,000 ×g for
20 min at 4 °C. We extracted the top gradient layer, which contained the nuclear
proteins, and washed and resuspended the proteins in 0.15 M NaCl.
Protein concentrationsweremeasuredbefore immunoprecipitation. Equal amounts of
nuclear proteins isolated fromHASMCs treatedwithorwithoutTNFαwere resuspended in
coldRIPEbuffer (Tris–HCl,NaCl SDS, sodiumdeoxycholate, TritonX-100), and incubatedon
ice for 20 min with proteinase inhibitor. The solution was passed through a 25G1 needle
(Cat#305125, Franklin lakes, NJ) to shear the DNA and then centrifuged at 3000 ×g for
10min. The supernatantwasmixedwith10 μl (1:100dilution) nonspeciﬁcmouse antibody
(Cat#2367, Cell Signaling, Danvers,MA) for 1 h at 4 °C, and thenmixedwith 45 μl protein A
magnetic beads (cat#S1425S, Biolabs) for 1 h at 4 °C for magnetic puriﬁcation. Finally, the
supernatant solutionwas mixed with mouse anti-NonO antibody (20 μl at 1:100 dilution,
Cat#MA3-2024, Afﬁnity Bioreagents, Golden, CO) and incubated overnight at 4 °C.
Magnetic beads (45 μl) labeled with protein A, which has a high afﬁnity for mouse IgG,
were used to pulldownNonO protein complexes, which were washed 3× with RIPE buffer
and once with TBE buffer. NonO-binding proteins were cleaved from the beads in 50 μl
SDS-PAGE buffer by boiling proteins for 5 min at 100 °C.
2.5. 1-D electrophoresis and mass spectrometry
Nuclear extracts were subjected to immunoprecipitation using anti-NonO antibody
and subsequently subjected to protein separation using 1D SDS-PAGE. Then, the gels were
treated with colloidal Coomassie stain to visualize protein bands. Well-resolved protein
bandswere excised from the gel and subjected to in-gel trypsin digestion, and subsequent
isolation of tryptic peptides. Isolated peptides were analyzed by tandem mass spectro-
metry on an Applied Biosystems/MDS Sciex 4800 MALDI-TOF/TOF instrument. The
proteins were identiﬁedwith the use of GPS Explorer software (v 3.5) with the embedded
Mascot® (Matrix Science, London) search engine using the SwissProt database limited to
queries against the Homo sapiens sub database (release 51; 16,603 entries).
2.6. Chromatin immunoprecipitation (ChIP) assay
A ChIP assay kit (Cat#17-295, Upstate, New York, NY) was used per manufacturer's
protocols. HASMCs treatedwith orwithout TNFαwere cross-linkedwith1% formaldehyde
at 37 °C for 10 min and rinsed with cold phosphate-buffered saline (PBS). Cell lysis was
performed in SDS-lysis buffer by incubation on ice for 10 min. The chromatin was
fragmented to pieces of 200 to 1000 bp by sonication using a Soniﬁer II 450 (Brason,
Danbury, CT) with a 3-mm tip set at a duty cycle 20 and output level 2. Supernatants were
collected by centrifuging cell pellets at 15,000 ×g for 10 min at 4 °C. We pre-cleared
supernatants by rotating with 75 μl salmon sperm DNA/protein A agrose-50% slurry for
30 min at 4 °C. Immunoprecipitation was performed with 2 μg acetyl-histone antibodies
from acetyl-Histone antibody sampler kit (Cat#9927, Cell signaling) at 4 °C overnight. A
salmon sperm DNA/protein A agarose slurry (60 μl) was added to the solution for an
additional 1-hour incubation at 4 °C. The precipitates of protein A agrose/antibody/
chromatin complexwerewashed twice (5min each at 4 °C)with low-salt buffer, oncewith
high-salt buffer, and once with LiCl buffer. The immune complexes were resuspended in
250 μl elution buffer for 15 min. After the elutes were heated at 65 °C for 4 h to reverse
cross-linking by addition of 20 μl 5 mol/l NaCl, 10 μl 0.5 mol EDTA and proteinase K
treatment, DNA was extracted by phenol/chloroform and precipitated with ethanol.
The recovered DNA resuspended for use in PCR was analyzed on 1.5% agarose gel. The
primers for PCR were 5′-CTCCCTGGCGCTGCCATCGCG-3′ spanning from −60 to −39 bp and
5′-CACCTGGAAAGTGGGACGAGAGG-3′ from+83 to+104bpof theP4Hα1gene.Wealsoused
anti-human NonO antibody (Bethyl), anti-human-DJ-1 antibody (Cat#2134, Cell signaling),
anti-oxidized-DJ-1 antibody (Cat#HCA024, AbD Serotec, Kidlington, UK), and anti-Di-methyl
H3 (lys9) antibody (Cat#9753, Cell Signaling) instead of anti-acetyl-histone antibody for the
immunoprecipitation process to perform the transcription factor-speciﬁc ChIP assay.
2.7. Western blot
Nuclear proteinswere extracted fromHASMCs after various treatments. Proteinswere
separated in 10% SDS-PAGE gel and transferred to nitrocellulose membranes. Several
antibodies, including anti-JNK1 (Cat #9252, Cell Signaling), anti-MKK4 (Cat#9152, Cell
Signaling), anti-NonO, anti-DJ-1, anti-oxidized-DJ-1 and anti-HDAC antibodies (Cat#9928,
Fig. 1.Wild-type MKK4 and JNK1 adenovirus suppress P4Hα1 expression in human aortic smooth muscle cells (HASMCs). A. Levels of P4Hα1 mRNAwere measured by quantitative
real-time RT-PCR from HASMCs infected with 30, 60, and 100 μl wild-type and dominant negative MKK4 adenovirus. **Pb0.01, by Student's t-test for comparisons between cells
treated with different doses of MKK4 and control cells. House-keeping control β-actin was regarded as 1, i.e. 100% expression. B. Western blot results with anti-MKK4 antibody
showing overexpression of MKK4 in HASMCs infected with MKK4 adenovirus. β-actin was used as a control. C. P4Hα1 mRNA levels were determined by RT-PCR from HASMCs
infected with 30, 60, and 100 μl wild-type and dominant negative JNK1 adenovirus. **Pb0.01, by Student's t-test for comparisons between cells treated with different doses of JNK1
and control cells. House-keeping control β-actin was regarded as 1, i.e. 100% expression. D. Western blot result with anti-JNK1 antibody showing overexpression of JNK1 in HASMCs
infected with JNK1 adenovirus. β-actin was used as a control.
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were diluted 1:1000 for the assay. Anti-mouse IgG-HRP conjugate (1:5000, Cat#7076,
Cell Signaling) or anti-rabbit IgG-HRP conjugate (1:5000, Cell signaling) was used as a
secondary antibody to detect the bands, which were visualized with ECL plus reagents.
2.8. Statistical analyses
All quantitative data are presented as means±SD. Between group differences were
compared using the Student's t-test, and among group differences were analyzed using one-
way ANOVA. Two-tailed Pb0.05 was regarded as statistically signiﬁcant. We used the SPSS
v14.0 for Windows (SPSS Inc., Chicago, IL) for statistical analyses.
3. Results
3.1. TNFα suppresses P4Hα1 expression throughMKK4 and JNK1 pathways
In HASMCs with overexpressed MKK4, we found that P4Hα1
mRNA levels were reduced to less than 30% by comparing the wild-
type with the dominant negative MKK4 overexpression. A dose-
dependent effect was noted from 30 μl to 100 μl MKK4, whereas the
effects at 10 μl or 20 μl were unremarkable (Fig. 1A). The over-
expression of MKK4 was conﬁrmed by Western blot (Fig. 1B). Similar
suppressive effects were also observed for cells with overexpression of
JNK1 (Fig. 1C and D). In the experiments described below, infecting
HASMCs with 100 μl MKK4 or 100 μl JNK1 adenovirus for 24 h
was used as the standard treatment condition. These data suggest
that the MKK4-JNK1 pathway is responsible for TNFα-mediated
P4Hα1 suppression. Thus, in the following experiments, we used
TNFα and either MKK4 or JNK1 to study the downstream molecular
mechanisms.
3.2. NonO is a transcription factor responsible for TNFα-MKK4-JNK1-
mediated P4Hα1 suppression
To evaluate the role of NonO in the TNFα-MKK4-JNK1-mediated
suppression of P4Hα1,we usedNonO siRNA to suppress NonO expression
beforeMKK4and JNK1overexpression.RT-PCRwasperformed tomeasure
P4Hα1mRNA levels at 24 h. NonO silencing abolished almost 60%–70% of
the MKK4- (Fig. 2A) or JNK1-mediated (Fig. 2B) P4Hα1 suppression. In
contrast, the dominant negative forms of MKK4 or JNK1 or NonO siRNA
alone did not affect the expression of P4Hα1.
We evaluated whether overexpression of MKK4 or JNK1 or TNFα in
HASMCs regulatedNonOexpression.None of these factors changed the
protein levels of NonO in HASMCs (Fig. 2C). Using the ChIP assay in
which anti-NonO antibody was used for immunoprecipitation, we
showed that JNK1 overexpression signiﬁcantly increased the binding
between TaRE within the P4Hα1 promoter region and the NonO pro-
tein (Fig. 2D), which was the same as the effects by TNFα as shown
previously [10]. In contrast, overexpression of the dominant negative
JNK1 had no effect. This ﬁnding suggests that NonO is responsible for
the TNFα-MKK4-JNK1-induced pathway of P4Hα1 suppression.
3.3. DJ-1 is involved in TNFα-MKK4-JNK1-NonO-mediated P4Hα1
suppression
Although NonO was found to be involved in TNFα-MKK4-JNK1-
mediated P4Hα1 suppression, we studied other nuclear proteins that
may be involved in the regulation. By subjecting the anti-NonO anti-
body-precipitated nuclear protein complex to 1-D electrophoresis and
LC-MS/MS investigation, we identiﬁed a list of nuclear proteins inFig. 2. Silencing NonO abolishes theMKK4-JNK1-mediated P4Hα1 suppression. A. Expression
measured by RT-PCR after HASMCs were infected with 100 μl wild-type and dominant negati
expression. B. Effects of NonO silence on HASMCs infected with 100 μl wild-type and domina
among different treatment conditions. ⁎Pb0.05, ⁎⁎Pb0.01, by Student's t-test for comparisons
was regarded as 1, i.e. 100% expression. C. NonO expression in HASMCs treated with TNFα, M
type or dominant negativeMKK4 or JNK1 adenovirus for 24 h, and 100 ng/ml TNFαwas added
control. D. HASMCs were infected with 100 μl wild-type and dominant negative JNK1 ad
immunoprecipitation. PCR primers covering the −60 to +104 bp region of the P4Hα1 promobinding with NonO protein (data not shown). Among them, DJ-1 was
the only protein found in TNFα-treated HASMCs that could potentially
be involved in NonO-mediated gene regulation. After DJ-1 expression
was silenced by DJ-1-speciﬁc siRNA in HASMCS, we observed a 50%
recovery of P4Hα1 expression in HASMCs treated with TNFα or JNK1
(Fig. 3A).
Like the effects on NonO protein, neither JNK1 nor TNFα affected
the protein levels of DJ-1 (Fig. 3B). To examine the effect of DJ-1 on the
NonO–TaRE interaction, HASMCs were treated with TNFα and JNK1
with or without DJ-1 siRNA. Using the ChIP assay with the anti-NonO
antibody for immunoprecipitation, we showed that TNFα- or JNK1-
induced NonO–TaRE binding was abolished when the expression
of DJ-1 was suppressed by gene speciﬁc siRNA (Fig. 3C). This ﬁnd-
ing suggests that DJ-1 is involved in the NonO–P4Hα1 promoter
interaction.
Because TNFα activation can cause oxidative stress and oxidatively
modify DJ-1, we used Western blot analysis to detect oxidized DJ-1 in
both total nuclear proteins and anti-NonO-immunoprecipitated
nuclear proteins. TNFα treatment resulted in an increase in oxidized
DJ-1, which was also seen in NonO-bound DJ-1 (Fig. 3D). Furthermore,
the ChIP assay (with anti-oxidized DJ-1 antibody) showed DJ-1–TaRE
binding, which was abrogated by NonO siRNA (Fig. 3E). In contrast, no
direct binding was seen between native DJ-1 and TaRE. These ﬁndings
indicate TNFα-induced oxidized DJ-1 rather than native DJ-1 could
play a role in bringing the NonO protein to the TaRE element.
3.4. Role of histone acetylation in TNFα-MKK4-JNK1-NonO-mediated
P4Hα1 suppression
To understand how TNFα-MKK4-JNK1-NonO regulates P4Hα1
promoter activity,we studied the histone (H3 andH4) phosphorylation
and acetylation status in HASMCs treated with TNFα or JNK1. Anti-H3
or H4 antibodies were used for immunoprecipitation, and primers for
the TaRE region within the P4Hα1 promoter were used for PCR
ampliﬁcation in the ChIP assay. As shown in Fig. 4A, the H3 serine 10
residue (H3S10) was phosphorylated in HASMCs; TNFα treatment did
not change the phosphorylation status. H3 lysine 23 (H3L23) and H4
lysine 8 (H4L8) were acetylated and not modiﬁed by TNFα or JNK1.
Furthermore, H3 lysine 18 (H4L18) was not deacetylated, and further
treatment with TNFα or JNK1 did not change the deacetylation sta-
tus (Fig. 4A). In contrast, although TNFα or JNK1 induced H4 lysine 12
(H4L12) acetylation, the treatments induced deacetylation at H3 lysine
9 (H3L9) (Fig. 4B).
To further study TNFα- or JNK1-induced histone modiﬁcations
within the TaRE region of the P4Hα1 promoter, we treated HASMCs
with either 20 μM HATI (anacardic acid) or 500 ng/ml HDAC inhibitor
(TSA). HATI abolished the TNFα-induced H4L12 acetylation, and the
HDAC inhibitor abrogated TNFα-induced H3L9 deacetylation (Fig. 4C).
These data suggest thatH4L12 acetylation andH3L9 deacetylationmay
be involved in TNFα-MKK4-JNK1-induced P4Hα1 suppression.
3.5. Effects of NonO on TNFα-JNK1-mediated histone modiﬁcation
NonO is essential for TNFα-induced P4Hα1 suppression, and TNFα
alters histone modiﬁcation in the TaRE region of the P4Hα1 promoter;
therefore, studying the involvement of NonO in P4Hα-TaRE histone
modiﬁcation is a logical approach. Fig. 5A shows that silencingNonOby
gene speciﬁc siRNA had no effect on TNFα-induced H4L12 acetylation.of NonOwas silenced by transfection of NonO-speciﬁc siRNA. P4Hα1mRNA levels were
ve MKK4 adenovirus for 24 h. House-keeping control β-actinwas regarded as 1, i.e. 100%
nt negative JNK1 adenovirus. The levels of P4Hα1 mRNAwere measured and compared
between cells with different treatments and control cells. House-keeping controlβ-actin
KK4, and JNK1 was measured byWestern blot. HASMCs were infected with 100 μl wild-
to cells for 8 h. Anti-NonO antibodywas used as primary antibody;β-actinwas used as a
enovirus. The ChIP assay was performed, and anti-NonO antibody was used for the
ter were used to amplify recovered protein-bound DNA.
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tion. Furthermore, silencing NonO eliminated TNFα-inducedmethyla-
tion of H3L9 (Fig. 5B).We analyzed the effects of histone modiﬁcation on the binding
afﬁnity between NonO protein and the TaRE element in the P4Hα1
promoter by treating HASMCs with HATI or TSA. Fig. 6A shows
Fig. 3. Effects of silencing DJ-1 on TNFα-JNK1-induced suppression of P4Hα1. A. DJ-1-speciﬁc siRNAwas applied to suppress DJ-1 expression. HASMCs were infectedwith 100 μl wild-
type and dominant negative JNK1 adenovirus or treated with 100 ng/ml TNFα. P4Hα1mRNA levels were measured by quantitative RT-PCR. ⁎Pb0.05, ⁎⁎Pb0.01, by Student's t-test for
comparisons between cells treated with JNK1 or TNFα and control cells. House-keeping control β-actin was regarded as 1, i.e. 100% expression. B. Western blot results with anti-DJ-1
antibody showing expression of DJ-1 in HASMCs treated with or without 100 μl wild-type JNK1 adenovirus or with100 ng/ml TNFα. C. ChIP assay examining the binding of NonO
protein with TaRE element (−32 bp to +18 bp) in the P4Hα1 promoter. Anti-NonO antibody was used in the ChIP assay in HASMCs treated with or without 100 ng/ml TNFα or with
100 μl wild-type JNK1 adenovirus with or without prior DJ-1 siRNA silencing. PCR was used to amplify protein-bound TaRE P4Hα1 promoter. D. Detection of oxidized DJ-1 in anti-
NonO antibody pulldown proteins or total proteins from HASMCs treated with or without 100 ng/ml TNFα. E. ChIP assays were performed using anti-DJ-1 antibody or anti-oxidized
DJ-1 antibody to study DJ-1–TaRE or oxidized DJ-1–TaRE interactions in HASMCs treated with or without 100 ng/ml TNFα or with 100 μl wild-type JNK1 adenovirus. NonO-speciﬁc
siRNA was applied to silence NonO protein expression.
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Fig. 3 (continued ).
1523C. Zhang et al. / Biochimica et Biophysica Acta 1783 (2008) 1517–1528that NonO–TaRE binding was signiﬁcantly reduced when histone
acetylation was inhibited by HATI (20 μM). In addition, HATI
treatment reversed the TNFα-JNK1-induced suppression of P4Hα1
expression (Fig. 6B). In contrast, deacetylation inhibition by the
HDAC inhibitor TSA (0.5 μM) did not affect NonO–TaRE binding
(Fig. 6A). However, TSA treatment recovered the TNFα-JNK1-
mediated suppression of P4Hα (Fig. 6C). Although TSA and HATI
had opposite effects on histone acetylation, both appeared to
reverse TNFα-JNK1-induced P4Hα1 suppression. This effect was
accompanied by the reduced NonO–TaRE interaction induced by
TNFα-JNK1 in cells treated with HATI (Fig. 6A) when TSA had no
effect on the TNFα-JNK1-induced NonO–TaRE interaction. These
ﬁndings suggest that TNFα-JNK1 treatment may induce H4L12
acetylation, which promotes the binding of NonO to TaRE. This
binding then causes H3L9 deacetylation and methylation, which is
responsible for reduced P4Hα1 promoter activity.
To study how NonO is involved in histone modiﬁcation, we
conducted a co-immunoprecipitation assay. Nuclear proteins were
extracted from HASMCs treated with or without TNFα. NonO
antibody was used to pull down NonO-binding proteins, which
were then subjected to Western blot analysis with anti-HDAC
antibodies. TNFα treatment signiﬁcantly increased the NonO–
HDAC1 and NonO–HDAC2 interactions (Fig. 7). We noted binding
of HDAC3 to NonO, but this interaction was not affected by TNFα
treatment (Fig. 7). No interaction was detected between NonO and
HDAC4, HDAC5, HDAC6, and HDAC7, either with or without TNFα
treatment.4. Discussion
Inﬂammation is a double-edged sword. Controlled inﬂammation
is essential for remodeling of the myocardium and vascular wall,
whereas uncontrolled inﬂammation leads to excessive tissue destruc-
tion and the eventual development of cardiovascular disease. Of the
plethora of inﬂammatory cytokines, TNFα is one of the most potent
ones implicated in the development of cardiovascular diseases,
such as atherosclerosis [19]. Previously, we have identiﬁed the TNFα
response element (TaRE) at −32 to +18 bp in the P4Hα1 promoter,
which binds NonO as a transcription factor in response to TNFα-
mediated P4Hα1 suppression. In addition, we have suggested that
the ASK1-JNK pathway may be activated by TNFα. In the current
study, we have shown that the activation of TNFα-ASK1-MKK4-JNK1-
NonO is essential for P4Hα1 suppression; knock-down of any of the
molecules in the signaling pathway relieves the suppression of P4Hα1.
In addition, oxidized DJ-1 induced by TNFα treatment appears to be
essential for the NonO–TaRE interaction, and NonO could also be
phosphorylated for the interaction with P4Hα1 promoter. Further-
more, our ﬁndings showed that TNFα-JNK1 could induce H4L12 ace-
tylation. Acetylated H4L12 recruited NonO to the TaRE region, which
resulted in the deacetylation of H3L9. These consecutive reactions
inactivate transcription of P4Hα1.
Several intracellular pathways could be triggered following TNFα
activation during inﬂammation. The importance of JNK in the TNFα
downstream pathway appears to correlate with transcriptional ac-
tivity [20]. To activate JNK, TNFα binds to TNFR1 on the cell surface
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Fig. 5. Effects of NonO on TNFα-induced histone acetylation/deacetylation andmethylation. A. NonO-speciﬁc siRNAwas transfected into HASMCs treated with or without TNFα. ChIP
assay was performed using anti-acetyl-H4 lysine 12 or anti-acetyl-H3 lysine 9 antibodies. Histone-bound DNAwas ampliﬁed by primers covering −60 to +104 bp region of the P4Hα1
promoter. Silencing NonO did not affect TNFα-induced H4 lysine 12 acetylation but did partially restore the H3 lysine 9 acetylation induced by TNFα treatment. B. Anti-methyl-H3
lysine 9 antibody was used in the ChIP assay in HASMCs treated with or without 100 ng/ml TNFα or NonO-speciﬁc siRNA. NonO silence by gene speciﬁc siRNA blocked TNFα-induced
H3 lysine 9 methylation.
1525C. Zhang et al. / Biochimica et Biophysica Acta 1783 (2008) 1517–1528and activates downstream cascades [21,22]. The ﬁnding that JNK-
speciﬁc (SP600125) and ASK1-speciﬁc inhibitors (thioredoxin) pre-
vent TNFα-mediated P4Hα1 suppression suggests the involvement of
the ASK1-JNK1 pathway [10]. Using the wild-type and dominant
negative MMK4 and JNK1 overexpression vectors in this study, we
validated the requirement of the ASK1-MKK4-JNK1 pathway in TNFα-
mediated P4Hα1 suppression. Our results support previous ﬁndings
that ASK1-MKK4-JNK1 is a classical inﬂammatory pathway [23,24].
Using 2-D gel electrophoresis and MALDI-TOF, we identiﬁed
another transcriptional factor, DJ-1, involved in the NonO–TaRE
complex. A 20KD conserved protein, DJ-1 binds to RNA-binding pro-
teins to regulate RNA–protein interaction and indirectly regulates
the androgen receptor (AR) [11,25,26]. DJ-1 expression may be sti-
mulated by several cytokines, including TNF-related-apoptosis-in-
ducing-ligand/Apo-2L (TRAIL) [27]. Other studies have also reported
that DJ-1, together with NonO, regulates the neuroprotective gene-
tic program in the pathogenesis of Parkinson's disease [28,29]. DJ-1
is specially responsive to oxidative damage which usually leads to
oxidative modiﬁcations of DJ-1 [30]. In our study, DJ-1 was con-
stitutively expressed in HASMCs. Treatment with TNFα, however,Fig. 4. TNFα-JNK1 inducedmodiﬁcation. ChIP assays were performedwith speciﬁc histone (H
to +104 bp region of the P4Hα1 promoter were used to amplify histone-bound DNA in PCR
acetyl-H3 lysine23, acetyl-H4 lysine8 and acetyl-H3 lysine18 antibodies. Experiments show
sites. B. ChIP assay using anti-acetyl-H4 lysine 12 or anti-acetyl-H3 lysine 9 in cells treated w
and H3-lysine 9 deacetylation. C. HASMCs treated with or without TNFαwere further treated
anti-acetyl-H4 lysine 12 or anti-acetyl-H3 lysine 9 antibodies. HATI treatment inhibited the T
H3 lysine. Exposure to HATI or TSA alone did not change the acetylation status at lysine 9 oinduced oxidative modiﬁcation of DJ-1, which facilitated the NonO–
TaRE interaction. The role of DJ-1 in the NonO–TaRE interaction was
further supported by our studies using DJ-1-speciﬁc siRNA and the
ChIP assay, in which oxidized but not native DJ-1 interacted with the
NonO–TaRE complex.
Chromatin/histone modiﬁcation is a critical process in transcrip-
tional regulation. Several types of histone modiﬁcations, includ-
ing acetylation, phosphorylation, and methylation, alter the tertiary
structure of chromatins to make them accessible to transcriptional
factors or, if tightly packed, inaccessible to all factors [31,32]. Many
inﬂammatory cytokines trigger histone modiﬁcation at different sites
[33,34]. Several pathways, including JNK and NFκB, participate in
TNFα-induced histone acetylation in which histone 4 could be hyper-
acetylated by JNK [35,36]. Our experiments show that TNFα-JNK
induce acetylation at H4L12, resulting in the formation of an inactive
chromatin state, which is consistent with the previous hypothesis
[37]. The additional H3L9 methylation may further shut down tran-
scription [38,39]. Previous studies showing that H3L9 methylation is
usually followed by its deacetylation support our ﬁndings [40]. In fact,
H4L12 acetylation and H3L9 methylation as combinatorial histone) antibodies in HAMSCs treated with or without TNFα or JNK1. Primers covering the −60
. A. ChIP assays using anti-phospho-H3 serine10, acetyl/phospho-H3 lysine9/serine10,
no change in the acetylation or phosphorylation in H3 and H4 at the listed amino acid
ith or without TNFα or JNK1. TNFα or JNK1 treatment induced H4-lysine 12 acetylation
with 20 μMHATI or 500 ng/ml TSA (HDAC inhibitor). ChIP assays were performed using
NFα-induced H4 lysine12 acetylation; TSA blocked the TNFα-induced deacetylation of
f H3 and lysine 12 of H4.
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Fig. 8. Diagramofmechanisms inTNFα-mediated P4Hα1 suppression. Potential pathways
for TNFα-induced P4Hα1 suppression. It appears that TNFα ﬁrst oxidizes DJ-1, phos-
phorylates NonO and acetylates H4 lysine 12. This effect is followed by NonO–P4Hα1
promoter interaction, which is facilitated by the oxidized DJ-1. This interaction leads to
HDACs binding to the NonO–TaRE complex, which, in turn, induces deacetylation and
methylation of the H3 lysine 9; the joint actions suppress P4Hα1 transcription.
Fig. 7. Interaction between NonO and HDACs. Anti-NonO antibody was used to
immunoprecipitate nuclear proteins extracted from HASMCs treated with or without
TNFα. The pulldown NonO-binding proteins were then subjected to Western blot
analysis with antibodies against HDAC1, 2, 3, 4, 5, 6 and 7. HDAC1 and HDAC2 binding
with NonO was increased by TNFα treatment. Minimal change was noted in HDAC3,
with no binding with HDAC 4, 5, 6, and 7.
1527C. Zhang et al. / Biochimica et Biophysica Acta 1783 (2008) 1517–1528modiﬁcations represent an “imprint” for inactive chromatin [41].
This effect is consistent with our ﬁndings. Synchronized H4L12
acetylation and H3L9 deacetylation would reinforce the inactive
chromatin status within the P4Hα1 promoter region. Thus, TNFα-
JNK1-induced acetylation at H4L12 and deacetylation and methyla-
tion at H3L9 would be sufﬁcient to silence P4Hα1 expression. The
sufﬁciency of HATI (anacardic acid) as an acetylation inhibitor and TSA
as a deacetylation inhibitor in histone modiﬁcation was identiﬁed by
the fact that HATI abolished the TNFα-induced H4L12 acetylation and
HDAC inhibitor abrogated TNFα-induced H3L9 deacetylation. The
elimination of TNFα-JNK1-mediated P4Hα1 suppression by treatment
with HATI or TSA suggests that histone modiﬁcation is crucial in
TNFα-mediated P4Hα1 suppression.
According to our ﬁndings, HATI inhibited H4L12 acetylation, which
led to the disruption of NonO–TaRE binding. However, silencing of
NonO did not interfere with H4L12 acetylation caused by TNFα. These
ﬁndings suggest that acetylation at H4L12 is essential for NonO–TaRE
binding. Although TSA-induced acetylation of H3L9 had no effect on
NonO–TaRE binding, NonO silencing signiﬁcantly reversed TNFα-
induced H3L9 deacetylation. This ﬁnding suggests that NonO–TaRE
binding is necessary for deacetylation at H3L9. In studies of the
mechanisms of NonO-associated histone acetylation/deacetylation,
we showed that the binding of HDAC1/HDAC2 with NonO was sig-
niﬁcantly increased in HASMCs treated with TNFα. The binding
between HDAC1/2 and NonO–TaRE may contribute to the deacetyla-
tion of H3L9. Other studies have shown that NonO could work
together with PTB-associated splicing factor (PSF) to enhance
recruitment of HDAC1 to target genes [42].
One limitation of our study is that the posttranslational modiﬁ-
cation of NonO has not been fully deﬁned. The NonO protein is
constitutively expressed in HASMCs treated with or without TNFα;
however, binding between the NonO protein and the P4Hα1 pro-
moter is seen only in TNFα-treated cells. Two possibilities can explain
this binding: posttranslational modiﬁcation of the NonO protein or
additional protein(s) that facilitate the binding of NonOwith TaRE. Our
ﬁndings suggest that DJ-1, oxidized by TNFα, could act as a bridging
protein that brings NonO to TaRE in the P4Hα promoter. However, our
initial experiments using 2-D electrophoresis, 2-D Western blot, and
speciﬁc phosphorylated protein stains show that TNFα treatment
may result in NonO phosphorylation, which could facilitate the di-
rect binding of NonO to the P4Hα1 promoter. Indeed, our preliminary
experiments using 2-D gel electrophoresis and phospho-protein
speciﬁc staining suggest possible phosphorylation of NonO by TNFα
treatment (online supplemental data). Furthermore, a global scanning
of site-speciﬁc phosphorylation by Olsen et al. has shown the possible
phosphorylation of the NonO protein at the threonine 450 site, whichFig. 6. Effects of histone acetylation on the NonO–P4Hα1–TaRE interaction. A. HASMCs were
used in the ChIP assay. NonO-bound DNA was ampliﬁed in PCR using primers covering the
inducedNonO–P4Hα1 promoter interaction,whereas TSA treatment had no effect on the inter
compared with baseline level. B. and C. Expression of P4Hα1 in HASMCs treated with TNFα (
and TSA reversed the suppressive effects on P4Hα1 expression by the TNFα-JNK1 activation, a
keeping control β-actin was regarded as 1, i.e. 100% expression.is the phosphorylation target of the JNK family [43]. Further study is
necessary to identify the amino acid residue(s) in the NonO protein
that is phosphorylated by TNFα, and the functional consequences of
NonO phosphorylation.
In summary, our study has established a tentative signaling path-
way for TNFα-induced suppression of P4Hα1. First, TNFα activates
the ASK1-MKK4-JNK1 pathway, which oxidizes DJ-1, possibly phos-
phorylates NonO, and induces H4L12 acetylation. This cascade of
events leads to the interaction of NonO with TaRE, which is follo-
wed by recruitment of HDACs and H3L9 deacetylation and methyla-
tion. Then ﬁnally, P4Hα1 transcription is inhibited (Fig. 8). Our study
is the ﬁrst to establish this chain of molecular events, which may
provide novel therapeutic targets for modulating pathologic proces-
ses induced by inﬂammation. Speciﬁcally, this inﬂammation-induced
suppression of collagen may be important to aortic aneurysm and
dissection and the stability of the ﬁbrous cap of atherosclerotic
plaques.
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region of −60 to +104 bp in the P4Hα1 promoter. HATI treatment attenuated the TNF-
action. However, TSA treatment of control cells did slightly increase the interactionwhen
100 ng/ml) or JNK1 (100 μl) with or without HATI (20 μM) or TSA (500 ng/ml). Both HATI
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